# Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-guselkumab-an-anti-interleukin-23-monoclonal-antibody/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrew Blauvelt,Kim Papp,C.E.M. Griffiths,B. Randazzo,Yasmine Wasfi,Yaung‐Kaung Shen,Shu Li,Alexa B. Kimball |
| Citations | 884 |
| DOI | 10.1016/j.jaad.2016.11.041 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.jaad.2016.11.041 |
| OpenAlex ID | https://openalex.org/W2570141807 |
| PMID | 28057360 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Alexa B. Kimball](https://scholariq.org/researchers/alexa-b-kimball/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.